Status:
COMPLETED
Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer
Lead Sponsor:
Geriatric Oncology Consortium
Collaborating Sponsors:
Sanofi
Conditions:
Prostate Cancer
Eligibility:
MALE
65+ years
Phase:
PHASE1
Brief Summary
This pilot study is designed to determine the feasibility and safety of administering docetaxel at various dosing levels on a bi-weekly schedule in older men with hormone refractory prostate cancer.
Detailed Description
The information obtained from this trial will help determine the feasibility and safety of administering docetaxel at various dosing levels on a bi-weekly schedule in this patient population. If the d...
Eligibility Criteria
Inclusion
- age ≥ 65 years;
- histologically confirmed adenocarcinoma of the prostate;
- metastatic disease;
- unresponsive or refractory to hormonal therapy, as defined by at least 1 of the following criteria: progression of bidimensionally measurable disease; progression of evaluable but not measurable disease (bone scan); at least 2 consecutive rises in PSA at least 1 week apart;
- patients must have serum testosterone levels \< 50 ng/mL at time of study entry. For patients who are medically castrated, lutenizing hormone releasing hormone analog must continue to maintain testicular suppression;
- prior nonsteroidal antiandrogens (flutamide, ketoconazole, bicalutamide, or nilutamide) allowed if disease progression occurred. No evidence of response after antiandrogen withdrawal within 4 weeks for patients treated with flutamide, ketoconazole, nilutamide and 6 weeks for patients treated with bicalutamide;
- chemotherapy naïve;
- full recovery from the effects of any prior surgery or radiation therapy. At least 4 weeks since any radiation therapy;
- ECOG performance status 0-2;
- adequate kidney, liver, and bone marrow functions;
- signed study-specific informed consent form.
Exclusion
- Concurrent chemotherapy or immunotherapy;
- Patients who have received an investigational drug within 4 weeks of registration;
- Prior or concurrent malignancies (other than surgically treated carcinoma in situ of the cervix and squamous or basal cell carcinoma of the skin) within the preceding five years;
- Serious medical or psychiatric illness which would prevent informed consent;
- Life expectancy \< 3 months;
- Active uncontrolled bacterial, viral, or fungal infection until these conditions are corrected or controlled;
- Known hypersensitivity to study drug or to other drugs formulated with polysorbate 80.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00215709
Start Date
July 1 2004
End Date
July 1 2007
Last Update
November 19 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baltimore, Maryland, United States, 21211